Case-control Indian buffet process identifies biomarkers of response to Codrituzumab
Related Experiment Video
Updated: Jan 27, 2026
Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
Published on: October 10, 2012
Melanie F Pradier1,2, Bernhard Reis3, Lori Jukofsky4
1Harvard University, Cambridge, MA, USA. melanie@seas.harvard.edu.
Background:
Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy. Biomarker analysis was performed to identify a responder population that benefits from treatment.
Methods:
A novel statistical method based on the Indian buffet process (IBP) was used to identify biomarkers predictive of response to treatment with Codrituzumab. The IBP is a novel method that allows flexibility in analysis design, and which is sensitive to slight, but meaningful between-group differences in biomarkers in very complex datasets RESULTS: The IBP model identified several subpopulations of patients having defined biomarker values. Tumor necrosis and viable cell content in the tumor were identified as prognostic markers of disease progression, as were the well-known HCC prognostic markers of disease progression, alpha-fetoprotein and Glypican-3 expression. Predictive markers of treatment response included natural killer (NK) cell surface markers and parameters influencing NK cell activity, all related to the mechanism of action of this drug CONCLUSIONS: The Indian buffet process can be effectively used to detect statistically significant signals with high sensitivity in complex and noisy biological data TRIAL REGISTRATION: NCT01507168 , January 6, 2012.
Insights
Codrituzumab shows promise in treating advanced hepatocellular carcinoma (HCC). A novel Indian buffet process method identified biomarkers, including NK cell markers, predicting treatment response in HCC patients.
Area of Science:
- Immunology
- Oncology
- Biostatistics
Background:
- Codrituzumab is a monoclonal antibody targeting Glypican-3 (GPC3), a marker in hepatocellular carcinoma (HCC).
- A phase II trial evaluated Codrituzumab in advanced HCC patients resistant to prior therapies.
- Biomarker analysis aimed to identify patient subgroups benefiting from Codrituzumab treatment.
Purpose of the Study:
- To identify predictive biomarkers for Codrituzumab treatment response in advanced HCC.
- To explore the utility of the Indian buffet process (IBP) for biomarker discovery in complex biological data.
- To validate known prognostic markers and discover novel predictive markers for HCC progression and treatment response.
Main Methods:
- Utilized a novel statistical approach, the Indian buffet process (IBP), for biomarker identification.
- Analyzed complex datasets to detect subtle yet significant differences between patient groups.
- Correlated biomarker expression and patient characteristics with treatment outcomes and disease progression.
Main Results:
- The IBP model identified distinct patient subpopulations based on biomarker profiles.
- Tumor necrosis, viable cell content, alpha-fetoprotein, and GPC3 expression were confirmed as prognostic markers.
- Natural killer (NK) cell surface markers and activity parameters emerged as predictive markers for Codrituzumab response.
Conclusions:
- The Indian buffet process is a sensitive and effective method for detecting significant signals in complex biological data.
- Biomarkers related to NK cell activity are predictive of Codrituzumab treatment efficacy in HCC.
- This study refines patient selection for targeted therapy in advanced HCC.
Related Concept Videos
01:15Introduction to Statistical Process Control
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:14Identifying Statistically Significant Differences: The F-Test
01:21Control System Problem
When forming a closed-loop system, issues can arise if the poles cross into the unstable region, leading to potential...
02:41Responses to Drought and Flooding
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...